EAU-EANM共识声明:前列腺特异性膜抗原PET/CT在前列腺癌患者中的作用及与[177Lu]Lu-PSMA放射配体治疗的关系
由21名前列腺癌多学科专家组成的小组,通过两轮e-Delphi问卷调查及一次为期1天的会议讨论,就PSMA PET/CT在前列腺癌中的应用及[177Lu]Lu-PSMA治疗相关问题形成共识。36条声明中33条达成共识,涵盖PSMA PET/CT的效用、临床使用、示踪剂选择、患者选择及接受[177Lu]Lu-PSMA治疗的转移性前列腺癌患者管理。
要点
- 36条声明中33条达成共识,涵盖PSMA PET/CT效用、临床使用、示踪剂选择、患者选择及[177Lu]Lu-PSMA治疗管理。
- 共识支持将PSMA PET/CT作为指导[177Lu]Lu-PSMA治疗的影像工具,并需有适当使用指征支持。
- 考虑患者为[177Lu]Lu-PSMA治疗候选者前,需先行PSMA-based影像检查。
核心结论
- 采用PSMA PET/CT作为指导[177Lu]Lu-PSMA治疗的影像工具应有适当使用指征支持。
- 专家组就大多数关于PSMA-based影像与治疗作用的声明达成共识,特别是PSMA-based影像在适合[177Lu]Lu-PSMA治疗患者中的应用及考虑患者为该治疗候选者前需行PSMA-based影像。
研究设计与样本
- 由21名来自不同学科的前列腺癌专家组成小组,接受主题议题及相关文献。
- 开发关于PSMA PET/CT和[177Lu]Lu-PSMA治疗拟议指导声明的问卷,第一轮e-Delphi远程完成。
- 随后进行为期1天的会议讨论,包括第二轮Delphi。
- 专家组成员使用9点Likert量表匿名投票(1=强烈反对,9=强烈同意),计算中位数评分,并采用RAND公司提出的方法评估共识。
诊断标准与关键数值
- 共识通过9点Likert量表投票评估,采用RAND公司方法判定共识,36条声明中33条达成共识。
临床应用与阅片要点
- 共识声明覆盖PSMA PET/CT效用、临床使用及示踪剂选择、患者选择、接受[177Lu]Lu-PSMA治疗的转移性前列腺癌患者管理。
- 专家组共识支持PSMA PET/CT作为指导[177Lu]Lu-PSMA治疗的影像工具,并需有适当使用指征。
- 专家组共识认为考虑患者为[177Lu]Lu-PSMA治疗候选者前需行PSMA-based影像。
局限性
- 组内偏倚是潜在局限性,因部分声明在1天会议讨论期间被改写。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
BACKGROUND: Prostate-specific membrane antigen (PSMA) positron emission tomography (PET)/computed tomography (CT) is useful for selected clinical indications in patients with prostate cancer (PCa) but it may have broader clinical utility owing to the emergence of lutetium-177-PSMA-617 ([177Lu]Lu-PSMA) therapy. However, robust data regarding the impact of PSMA PET/CT on patient management and treatment are lacking, and in many areas, the role of next-generation imaging has not been defined.
OBJECTIVE: To assess expert opinion on the use of PSMA-based imaging and therapy to develop interim guidance.
DESIGN, SETTING, AND PARTICIPANTS: A panel of 21 PCa experts from various disciplines received thematic topics and relevant literature. A questionnaire to assess proposed guidance statements regarding PSMA PET/CT and [177Lu]Lu-PSMA therapy was developed for completion remotely in a first e-Delphi round. A subsequent panel discussion was conducted during a 1-d meeting, which included a second Delphi round.
OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: Panellists voted anonymously on statements using a nine-point Likert scale from 1 = strongly disagree to 9 = strongly agree. Median scores were calculated and consensus was assessed using methods proposed by the Research and Development (RAND) corporation.
RESULTS AND LIMITATIONS: Statements were developed to cover the following topics: PSMA PET/CT utility, clinical use, and choice of tracer; patient selection; and management of patients receiving [177Lu]Lu-PSMA for metastatic PCa. Consensus was reached for 33/36 statements. In-group bias is a potential limitation, as some statements were rephrased during discussions at the 1-d meeting.
CONCLUSIONS: Adoption of PSMA PET/CT as an imaging tool to guide [177Lu]Lu-PSMA therapy should be supported by indications for appropriate use.
PATIENT SUMMARY: A panel of experts in prostate cancer reached a consensus for the majority of statements proposed regarding the role of prostate-specific membrane antigen (PSMA)-based imaging and therapy, particularly the use of PSMA-based imaging in patients suitable for [177Lu]Lu-PSMA therapy and the need to perform PSMA-based imaging before considering patients as candidates for this therapy.
引用
- Fanti, Briganti, Emmett, et al. EAU-EANM Consensus Statements on the Role of Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography in Patients with Prostate Cancer and with Respect to [177Lu]Lu-PSMA Radioligand Therapy. Eur Urol Oncol. 2022. PMID: 35697600. doi:10.1016/j.euo.2022.05.003
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。